Last reviewed · How we verify
Polidocanol with Glucose
Polidocanol is a sclerosing agent that causes endothelial damage and fibrosis of blood vessel walls, used in combination with glucose as a sclerosant for varicose veins and other vascular lesions.
Polidocanol is a sclerosing agent that causes endothelial damage and fibrosis of blood vessel walls, used in combination with glucose as a sclerosant for varicose veins and other vascular lesions. Used for Varicose veins, Telangiectasia and spider veins, Venous malformations.
At a glance
| Generic name | Polidocanol with Glucose |
|---|---|
| Also known as | Dodecylpolyethyleneglycolether, Aethoxysklerol, Varithena, Asclera |
| Sponsor | UPECLIN HC FM Botucatu Unesp |
| Drug class | Sclerosing agent |
| Modality | Small molecule |
| Therapeutic area | Vascular/Dermatology |
| Phase | FDA-approved |
Mechanism of action
Polidocanol is a non-ionic surfactant that damages the endothelial lining of blood vessels, triggering an inflammatory response that leads to vessel wall fibrosis and obliteration. When combined with glucose, the formulation enhances the sclerosing effect and improves the density and visibility of the solution for injection into varicose veins and telangiectasias. This causes the targeted vessels to collapse and be reabsorbed by the body.
Approved indications
- Varicose veins
- Telangiectasia and spider veins
- Venous malformations
Common side effects
- Injection site pain or burning
- Thrombophlebitis
- Hyperpigmentation at injection site
- Allergic reactions
- Necrosis (rare)
Key clinical trials
- CLaCS Using 0.2% Aetoxysklerol Foam and 70% Glucose for the Treatment of Lower Limb Telangiectasias (PHASE2)
- Lower Limb Sclerotherapy of Reticular Veins and Telangiectasias
- Vaginal Hygiene Wash as Adjunct Treatment in Bacterial Vaginosis (NA)
- Polidocanol Versus Glucose Treatment of Telangiectasia Trial (PHASE4)
- Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Treatment of Reticular Veins (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polidocanol with Glucose CI brief — competitive landscape report
- Polidocanol with Glucose updates RSS · CI watch RSS
- UPECLIN HC FM Botucatu Unesp portfolio CI